시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
유방암 액체 생검 시장 보고서 : 제품 및 서비스, 순환 바이오마커, 최종사용자, 지역별(2025-2033년)
Breast Cancer Liquid Biopsy Market Report by Product Services, Circulating Biomarker (Circulating Tumor Cells, Cell-Free DNA, Extracellular Vesicles, and Others), End User, and Region 2025-2033
상품코드 : 1753989
리서치사 : IMARC Group
발행일 : 2025년 06월
페이지 정보 : 영문 150 Pages
 라이선스 & 가격 (부가세 별도)
US $ 2,999 ￦ 4,131,000
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 3,999 ￦ 5,509,000
PDF & Excel (5 User License) help
PDF, Excel 보고서를 동일 사업장의 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,999 ￦ 6,887,000
PDF & Excel (Corporate License) help
PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

유방암 액체 생검 세계 시장 규모는 2024년에 1억 5,070만 달러에 달했습니다. 향후 IMARC Group은 2033년까지 5억 5,340만 달러에 달할 것으로 예상하며, 2025-2033년까지 14.77%의 연평균 성장률(CAGR)을 기록할 것으로 전망하고 있습니다. 유방암 유병률 증가, 비침습적 진단 방법으로의 전환, 지속적인 기술 발전, 암 연구에 대한 투자 급증 등이 시장 성장을 주도하고 있습니다.

유방암 액체 생검 시장 분석

유방암 액체 생검 시장 동향

유방암 유병률 증가

유방암의 전 세계 유병률 증가는 주요 촉진요인 중 하나입니다. 예를 들어, 세계보건기구(WHO)에 따르면 2022년에는 전 세계적으로 약 230만 명의 여성이 유방암 진단을 받고 약 67만 명이 사망할 것으로 예상됩니다. 마찬가지로 미국 유방암 재단에 따르면 미국에서는 여성 8명 중 1명이 일생 동안 유방암 진단을 받을 것이며, 2024년에는 약 31,720명의 여성과 2,800명의 남성이 침윤성 유방암 진단을 받을 것으로 추정됩니다. 유방암은 여전히 전 세계 여성들에게 가장 흔한 암 중 하나이기 때문에 액체 생검과 같은 조기 발견 및 모니터링 솔루션에 대한 수요가 증가하고 있습니다. 이러한 요인으로 인해 유방암 액체 생검 시장 점유율은 향후 몇 년 동안 상승할 것으로 예상됩니다.

조기 발견에 집중

유방암의 조기 발견은 환자의 예후를 크게 향상시키며, 액체 생검은 기존 영상 진단법보다 조기 발견을 가능하게 합니다. 예를 들어, 미국 국립의학도서관(National Library of Medicine)이 발표한 논문에 따르면, LB는 초기 단계의 암 진단, 종양의 성장과 재발 추적, 치료에 대한 환자의 반응 예측에 있어 가능성을 보여주고 있습니다. 또한 질병의 진행과 치료 효과를 추적하는 데 필수적인 지속적인 모니터링이 가능하여 현대 종양학에서 필수적인 도구가 되고 있습니다. 이러한 요인들은 유방암 액체 생검 시장 예측에 긍정적인 영향을 미치고 있습니다.

제품 혁신

유전체 시퀀싱, 분자생물학, 바이오인포매틱스 분야의 기술 혁신은 액체 생검 기술의 민감도, 특이성, 정확도를 높이고 있습니다. 예를 들어, 2023년 11월, DNA 시퀀싱 및 어레이 기반 기술 기업인 Illumina는 유전체 프로파일링을 위한 분산형 액체 생검 분석의 개선된 버전을 개발했습니다. 새로운 TruSight Oncology 500 ctDNA v2(TruSight Oncology 500 ctDNA v2)는 혈액에서 순환 종양 DNA(ctDNA)의 비침습적 포괄적 유전체 프로파일링(CGP)을 가능하게 하는 연구용 분석법입니다. 이러한 발전은 암의 조기 발견, 치료 효과 모니터링, 내성 돌연변이 식별에 도움을 주며, 임상에서 액체 생검의 채택을 촉진하고 유방암 액체 생검 시장의 성장을 촉진하고 있습니다.

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 유방암 액체 생검 시장

제6장 시장 내역 : 제품 및 서비스별

제7장 시장 내역 : 순환 바이오마커별

제8장 시장 내역 : 최종사용자별

제9장 시장 내역 : 지역별

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도

ksm
영문 목차

영문목차

The global breast cancer liquid biopsy market size reached USD 150.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 553.4 Million by 2033, exhibiting a growth rate (CAGR) of 14.77% during 2025-2033. The rising prevalence of breast cancer, shift towards non-invasive diagnostic methods, ongoing technological advancements, and surging investment in cancer research, are primarily driving the market's growth.

Breast Cancer Liquid Biopsy Market Analysis:

Breast Cancer Liquid Biopsy Market Trends:

Increasing Prevalence of Breast Cancer

The increasing global prevalence of breast cancer is one of the primary drivers. For instance, according to the World Health Organization (WHO), in 2022, nearly 2.3 million women were diagnosed with breast cancer, and approximately 670,000 died worldwide. Similarly, according to the National Breast Cancer Foundation, in the United States, 1 out of every 8 women will be diagnosed with breast cancer during their lifetime. In 2024, an estimated 310,720 women and 2,800 males will be diagnosed with invasive breast cancer. As breast cancer remains one of the most common cancers among women worldwide, the demand for early detection and monitoring solutions, like liquid biopsy, is rising. These factors are expected to propel the breast cancer liquid biopsy market share in the coming years.

Focus on Early Detection

Early detection of breast cancer significantly improves patient outcomes, and liquid biopsy allows for earlier detection than some traditional imaging methods. For instance, according to an article published by the National Library of Medicine, LB has demonstrated potential in diagnosing cancer at an early stage, tracking tumor growth and recurrence, and predicting patient response to therapy. It also enables continuous monitoring, which is essential for tracking disease progression and treatment response, making it an essential tool in modern oncology. These factors further positively influence the breast cancer liquid biopsy market forecast.

Product Innovations

Innovations in genomic sequencing, molecular biology, and bioinformatics are enhancing the sensitivity, specificity, and accuracy of liquid biopsy techniques. For instance, in November 2023, Illumina Inc., a DNA sequencing and array-based technology business, developed an improved version of their distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that allows for non-invasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood. These advancements help in early cancer detection, monitoring treatment efficacy, and identifying resistance mutations, which drives the adoption of liquid biopsy in clinical settings, thereby boosting the breast cancer liquid biopsy market growth.

Global Breast Cancer Liquid Biopsy Industry Segmentation:

Breakup by Product Services:

Currently, reagent kits account for the majority of the global market share

According to the breast cancer liquid biopsy market outlook, the increasing global incidence of breast cancer has heightened the need for better diagnostic, monitoring, and screening tools. As liquid biopsy becomes more commonly used, the demand for reagent kits that support these tests rises proportionally. Moreover, traditional tissue biopsies are invasive and can cause discomfort and complications. Liquid biopsy offers a non-invasive alternative, which is gaining popularity for both diagnostic and treatment monitoring purposes. This shift is a key driver for reagent kits used in liquid biopsy procedures, such as those for detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs).

Breakup by Circulating Biomarker:

According to the breast cancer liquid biopsy market analysis report, CTCs are cancer cells that have shed from the primary tumor into the bloodstream. The presence of CTCs in the blood correlates with disease stage and prognosis. Higher numbers of CTCs are often associated with advanced cancer and poorer outcomes. Moreover, cfDNA consists of small fragments of DNA released from tumor cells (also referred to as circulating tumor DNA or ctDNA) and other cells into the bloodstream. Moreover, analysis of cfDNA allows for the detection of specific mutations, such as those in the PIK3CA gene, TP53, or ESR1, which can guide treatment choices, especially for targeted therapies. Furthermore, extracellular vesicles (such as exosomes and microvesicles) are small membrane-bound particles released by cells, including cancer cells, into the bloodstream. EVs contain a variety of biomolecules, including proteins, RNA, DNA, and lipids, and can play a role in cell-to-cell communication.

Breakup by End User:

According to the breast cancer liquid biopsy market outlook report, reference labs often have access to the most cutting-edge technologies in liquid biopsy, including next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Their advanced infrastructure attracts demand from hospitals and physician labs that do not have these capabilities. Moreover, large hospitals, especially those with dedicated oncology centers, have a high volume of breast cancer patients requiring regular monitoring. Liquid biopsy offers a less invasive, faster alternative to traditional tissue biopsies for diagnosis, treatment monitoring, and recurrence detection. Furthermore, physical labs are often the first point of care for breast cancer screening. Liquid biopsies provide a more accessible and less invasive option for patients at high risk of breast cancer, allowing for earlier detection and intervention.

Breakup by Region:

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America dominates the global market.

According to the breast cancer liquid biopsy market statistics, breast cancer remains one of the most common cancers among women in North America, driving demand for improved diagnostic tools. Moreover, liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, which can be painful, risky, and difficult to perform, especially in advanced cancer cases. As a simple blood test, liquid biopsy is more appealing to patients, contributing to its growing adoption. Besides this, advances in liquid biopsy technologies, including next-generation sequencing (NGS), PCR-based methods, and improved ctDNA and CTC (circulating tumor cells) detection platforms, have significantly increased the accuracy and sensitivity of these tests. These innovations are driving wider clinical adoption of liquid biopsy for breast cancer diagnosis and monitoring.

Competitive Landscape:

The breast cancer liquid biopsy market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Breast Cancer Liquid Biopsy Market

6 Market Breakup by Product Services

7 Market Breakup by Circulating Biomarker

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기